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Cutting Inappropriate ICD Shocks: Long Arrhythmia-
Detection Time Strategy Confirmed 
 Programming implantable cardioverter defibrillators 
(ICDs) to delay the time they take to treat ventricular 
arrhythmias cuts mortality by 23% and inappropriate 
shocks by more than one-half in a meta-analysis 
encompassing ~4900 patients. The included studies were 
prospective and multicenter and covered both primary and 
secondary prevention and patients with either ischemic or 
nonischemic cardiomyopathy. The risk of syncope did not 
rise significantly with longer detection times, despite 
traditional concerns that lots of patients would not tolerate 
prolonged arrhythmia exposure before their ICD is 
allowed to deliver therapy, either shocks or antitachycardia 
pacing (ATP). Instead, the extra time frequently gave 
devices a better chance to exclude non–life-threatening 
arrhythmias like atrial fibrillation and to let otherwise self-
terminating ventricular arrhythmias play out on their own. 
Current nominal settings used by some ICD manufacturers 
are likely to be too aggressive, with arrhythmia detection 
times that in some cases may be as short as 1-3 s. These 
results highlight the importance of setting longer default 
ICD detection times. The analysis included 4896 patients 
from the MADIT-RIT, ADVANCE 3, and PROVIDE 
randomized trials and the RELEVANT nonrandomized 
study. Overall, 264 patients received appropriate shocks 
and 253 experienced inappropriate shocks at follow-up (12 
- 17 months). The relative risk (RR) of death from any 
cause was 0.77 (p=0.02) in the prolonged-detection-time 
groups compared with controls; the risks of inappropriate 
shocks and appropriate and inappropriate ATP also fell 
significantly. Why there were fewer deaths with longer 
detection times is unclear but it may derive from less 
exposure to potential hazards of shocks and ATP; 
inappropriate shocks may up mortality, and ATP poses a 
small risk of inducing ventricular fibrillation; or it may be 
due to some other factor, e.g. avoidance of treatment for 
multiple ICD therapies (e.g., prescription of 
antiarrhythmic drugs) (Scott PA et al, Heart Rhythm 2014; 
DOI:10.1016/j.hrthm.2014.02.009. Epub 2014 Feb 12).  
 
MRI Aids in Atrial Fibrillation Ablation Success 
 The Delayed Enhancement-MRI Determinant of 
Successful Catheter Ablation of Atrial Fibrillation 
(DECAAF) study, which shows that magnetic resonance 
imaging (MRI) can be used to detect the degree of atrial 
fibrosis and predict ablation success, is now published. 
Atrial tissue fibrosis in the left atrium contributes to the 
progression of atrial fibrillation (AF); the more fibrosis 
there is, the more likely the arrhythmia will persist 
following ablation. Briefly, atrial fibrosis estimated by 
delayed-enhancement MRI in 260 AF patients, including 
65% with paroxysmal AF, was a significant predictor of 
recurrence. Each 1% increase in fibrosis was associated 
with a 6% increased risk of recurrence. The extent of atrial 
disease was the only predictor of outcomes. When you 
look at MRI, you can predict the chance of patient having 
a recurrence, independent of the operator, experienced 
centers, and type of lesions. This is another major finding, 
that encircling the pulmonary veins with lesions as seen on 
the MRI was not important in terms of treatment success. 
At one year, 88% of patients with stage 1 fibrosis were free 
of AF. For those with stage 2, 3, or 4 fibrosis, respectively, 
69%, 55%, and 45% were free of recurrence at one year. 
At 475 days, 86%, 64%, 51%, and 35% of those with stage 
1, 2, 3, and 4 fibrosis were free of AF, respectively 
(Marrouche et al, JAMA 2014;311:498-506).  
 
Distinguishing Ventricular Arrhythmia Originating 
from the Right Coronary Cusp, Peripulmonic Valve 
Area, and the Right Ventricular Outflow Tract: Utility 
of Lead I 
 Outflow tract ventricular arrhythmias (OTVA) can be 
complicated to target for ablation when originating from 
either the periaortic or pulmonary valve (PV) region. Both 
sites may present with a small R wave in lead V1. 
However, the utility of lead I in distinguishing these 
arrhythmia locations is unknown. Thirty-six consecutive 
patients (mean age 41 ± 14 years) underwent catheter 
ablation for OTVA. OTVA origin was determined from 
intracardiac electrogram tracings and electro-anatomic 
maps. Observers blinded to results measured QRS 
waveform amplitude and duration from standard 12-lead 
ECG tracings. Measurements with highest diagnostic 
performance were modeled into an algorithm. Sites of 
successful ablation were anterior right ventricular outflow 
tract (RVOT; n = 6), posterior RVOT (n = 4), PV (n = 18), 
30 
 
and right coronary cusp (RCC; n = 8). Highest performing 
surface ECG discriminators were from lead I to V1 
vectors: RCC, lead I R wave≥1.5 mV, and V1 R wave≥2.0 
mV (sensitivity 87%, specificity 93%); PV, V1 R wave > 
0 mV, and lead I R/(R+S) ≤ 0.75 (sensitivity 78%, 
specificity 72%); anterior RVOT, V1 R wave = 0 mV, and 
lead I R/(R+S) <0.4 (sensitivity 67%, specificity97%); 
posterior RVOT, V1 R wave > 0 mV, and lead I R/(R+S) 
> 0.75 (sensitivity 75%, specificity 84%). Sequential 
algorithmic application of these criteria resulted in an 
overall accuracy of 72% in predicting site of OTVA origin. 
A relatively large R wave in lead I is seen with RCC origin 
but not PV origin (Ebrille et al, J Cardiovasc 
Electrophysiol, Epub Jan 8, 2014). 
 
Bacteremia Appears to Increase 30-Day Risk of MI or 
Stroke 
 Patients who had bacteremia mainly urinary tract 
infections, pneumonia, or sepsis when admitted to hospital 
were much more likely to have an MI or stroke within 30 
days, compared with healthy controls or patients 
hospitalized for other reasons. This study corroborates that 
acute infection may trigger cardiovascular events. It is the 
first study to demonstrate that many different bacterial 
infections may affect MI and stroke risk. The research 
suggests that bacteremia should be considered a risk factor 
for MI and stroke, but only for a short period of time after 
onset of infection, and it hints that infection with 
Staphylococcus aureus may confer a particularly high risk. 
Patients admitted with signs of acute infection and 
bacteremia/sepsis should be monitored closely for 
complications, and treated early with fluid therapy, 
oxygen, and antibiotics. Moreover, it seems prudent to 
increase vaccination efforts (e.g., influenza and 
pneumococcal vaccination), particularly in patients who 
already have established cardiovascular disease, since 
infection may trigger new cardiovascular events. Future 
studies are needed to clarify whether specific 
cardiovascular therapies (e.g., antithrombotic or anti-
inflammatory drugs) may reduce the risk of cardiovascular 
complications in patients with bacteremia, An estimated 
one million Americans have an acute MI or stroke each 
year, and it would be useful to understand how acute 
infections might trigger these events, but most previous 
studies lacked laboratory confirmation of infection. Using 
population-based databases, they identified 4389 patients 
(mean age 73 years) in Northern Denmark who had 
positive blood cultures when admitted to hospital (1992-
2010). The pathogens were E. coli, S. pneumoniae, S 
aureus, other bacteria, and fungi. Most patients had urinary 
tract infections or pneumonia, while others had central 
nervous system infections, endocarditis, and other 
infections. Based on age, gender, and date of admission, 
each patient was matched with ~5 patients hospitalized for 
other reasons and ~10 individuals in the general 
population. Researchers identified all incident MI and 
stroke events that occurred within 0-30 days, 31-180 days, 
and 181-365 days after the day of hospitalization. Patients 
with community-acquired bacteremia had a greatly 
increased risk of MI or stroke within 30 days. At 31-180 
days, these patients had a modestly higher risk of MI or 
stroke compared with healthy controls, but not compared 
with other hospitalized patients. No differences in 
cardiovascular risk were seen after >6 months. Increased 
efforts should be made to improve suboptimal vaccination 
rates among patients with cardiovascular disease. Further 
studies would be required to assess whether antiplatelet, 
beta-blocker, or statin therapies might result in lower 
cardiovascular complications and possibly better outcomes 
after acute infection (Dalager-Pedersen et al, Circulation 
2014; doi: 10.1161/CIRCULATIONAHA. 113.006699. Epub 
2014 Feb 12).  
 
In-hospital Switching of Oral P2Y12 Inhibitor  
 In the context of the GReek AntiPlatelet REgistry 
(GRAPE), Alexopoulos et al assessed the prevalence, 
predictive factors and short-term outcome of in-
hospital P2Y12 inhibitor switching in 1794 ACS 
patients undergoing PCI. Switching occurred in 636 
(35.5%) patients of which in the form of clopidogrel to 
a novel agent, novel agent to clopidogrel and between 
prasugrel and ticagrelor in 574 (90.4%), 34 (5.3%) and 
27 (4.3%) patients, respectively. Presentation to non 
PCI-capable hospital, bivalirudin use, age ≥75 years 
(inverse predictor), and regional trends emerged as 
predictive factors of switching to a novel agent. In-
hospital switching in initially clopidogrel treated 
patients was not accompanied by differences in the rate 
of major adverse cardiac events (MACE) or bleeding 
events compared with patients who started antiplatelet 
treatment with a novel agent since their admission. 
Reports with prasugrel use are in the same line of 
evidence. In contrast, in-hospital switching in initially 
clopidogrel treated patients was accompanied by a 
higher risk of BARC type 1, type 2 and any type 
bleeding and less ischemic events, when compared to 
patients receiving clopidogrel only. Of note, the 
observed difference in BARC any type bleeding was 
driven by BARC type 1 bleeding events. Both findings 
are in agreement with the described higher anti-
ischemic and bleeding potential of prasugrel and 
ticagrelor compared to clopidogrel. Having 3 oral 
P2Y12 inhibitors to select for clinical use in addition to 
aspirin in patients with acute coronary syndromes 
(ACS) undergoing PCI, in-hospital switching 
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represents a common clinical practice. Clinical factors 
and regional practice differences seem to affect the 
choice of this strategy, while in-hospital switching to a 
novel P2Y12 inhibitor may be associated with an 
increased risk of bleeding up to one month post 
treatment initiation (Alexopoulos et al, Am Heart J 
2014;167:68-76).  
 
Monitor Detects AF in Cryptogenic Stroke 
 An implanted cardiac monitor was much more effective 
at picking up atrial fibrillation (AF) than standard 
monitoring in patients with cryptogenic stroke in the 
CRYSTAL-AF trial. Because AF is one of the most 
important risk factors for stroke and the risk can be reduced 
greatly with anticoagulation therapy, such monitoring 
could bring about a significant reduction in recurrent 
stroke rates. Approximately 30% of strokes are labeled as 
cryptogenic, meaning no known cause. But patients with 
stroke of unknown etiology should not settle for this 
diagnosis after just 1 round of tests. Many will have AF, 
and finding it can prevent them from having a recurrent 
stroke. This idea of needing to pick up undiagnosed AF is 
not restricted to this 1 device, but we would say long-term 
cardiac monitoring is definitely coming into play, but how 
exactly we are going to do this is still very much open to 
question. We have to consider costs and logistics. If we did 
not have an effective treatment for AF, then this study 
would not be relevant, but we do have an effective 
treatment. Anticoagulation is the single most effective 
stroke prevention there is, having been shown to prevent 
about 70% of strokes, so the potential for benefit is huge. 
This is a very interesting device. There are many patients 
who have had a stroke, and we do a full workup and still 
cannot figure out why. This device picks up AF, which is 
a treatable cause of stroke; also, it could make a big 
difference. The CRYSTAL-AF trial included 441 patients 
who had had an unexplained stroke. All received at least 
24 hours of standard cardiac monitoring within 90 days of 
the stroke, and half were then tracked with an insertable 
monitor (Reveal XT, Medtronic), which can provide data 
continuously for up to 3 years. The device, which is about 
the size of a USB stick, is inserted under the skin with a 
minimally invasive 15- to 30-min outpatient procedure 
under local anesthetic. Results showed a far greater 
detection of AF in the group receiving the monitor vs the 
control group. Among patients in the study who were 
found to have AF, oral anticoagulants were prescribed for 
97% of cases. There were numerically fewer strokes in the 
device arm, but this study was not powered to show a 
reduction in stroke. The benefits of the insertable device 
far outweigh risks, noting that 2.4% of the devices had to 
be removed in the study because of complications, and the 
patients had no long-term problems. Results showed that 
in the control group, there were 121 ECGs, 32 24-hour 
Holter recordings, and 1 event recorder, but all these 
picked up only 4 cases of AF in 1 year in 220 patients, 
while 29 new cases were found in the device group. This 
shows how inadequate current methods of detecting AF are 
(International Stroke Conference - ISC 2014. Abstract 
LB11. Presented February 14, 2014).  
 
Aldosterone-Antagonist did not Reduce Mortality 
and Morbidity in Heart Failure (HF) Patients with 
Preserved Ejection Fraction. 
 A randomized clinical trial in patients with HF with 
preserved ejection fraction (HFPEF) has its researchers 
and some experts hopeful that there may finally be a 
drug for the disorder that can improve clinical 
outcomes. The study was negative, all agree: patients 
who took the aldosterone inhibitor spironolactone 
failed to show benefit for the clinical composite 
primary end point. But they did have significantly 
fewer heart-failure hospitalizations, a part of the 
primary end point, over the average follow-up of 3.3 
years in the trial, called Treatment of Preserved Cardiac 
Function Heart Failure with an Aldosterone Antagonist 
(TOPCAT). Overall, all-cause hospitalizations and all-
cause mortality did not seem to be meaningfully 
impacted by this drug. And we have to acknowledge 
that, minus the careful [creatinine and serum 
potassium] monitoring that occurred in the clinical 
trial, the prevalence of worsening renal function and 
hyperkalemia would likely be more common in clinical 
practice. When physicians use a mineralocorticoid 
antagonist in patients with HFPEF, they agree on the 
importance of good safety monitoring, especially for 
renal function, and look carefully for any other reason 
that would further corroborate the decision to give any 
aldosterone antagonist, like hypertension, for example. 
TOPCAT randomized 3445 heart-failure patients at 
least aged 50 with an LVEF>45% at 270 sites in 6 
countries to receive the aldosterone antagonist or 
placebo. Spironolactone was titrated up to 30 to 45 
mg/day. There were no significant differences in 
adverse events, except, more hyperkalemia with 
spironolactone and more hypokalemia on placebo; 
there were no hyperkalemia-related deaths (Shah et al, 
Circ Heart Fail 2014;7:104-115).  
 
Cardiac Resynchronization Therapy (CRT) in Mild 
Heart Failure Patients  
 Patients with mild – heart failure symptoms, left 
ventricular dysfunction and left bundle branch block 
(LBBB), early intervention with CRT-D was associated 
with a significant long term survival benefit. The MADIT-
32 
 
CRT trial showed that at 7 years of follow up, the 
cumulative rate of death from any cause among patients 
with LBBB was 18% among patients randomly assigned 
to CRT-D, as compared with 29% among those randomly 
assigned to defibrillator (D) therapy alone. The survival 
difference corresponded to 9 patients who would need to 
be treated with CRT-D to save one life within 7 years. The 
long-term survival benefit of CRT-D in patients with 
LBBB did not differ significantly according to sex, cause 
of cardiomyopathy (ischemic or nonischemic), or QRS 
duration. In contrast, CRT-D was not associated with any 
clinical benefit and possibly with harm in patients without 
LBBB. The lack of survival benefit associated with CRT-
D in patients without LBBB was consistent among those 
with a longer (>150 ms) or a shorter QRS duration (<150 
ms), and among patients with QRS morphologic findings 
showing RBBB or intra-ventricular conduction delay. The 
final study sample included the 1818 patients from 
MADIT-CRT for whom baseline ECG data were available 
(Goldenberg et al, N Engl J Med, Epub 2014 Mar 30).  
 
Is there a Place for Evolocumab in the Age of Statins? 
 LAPLACE-2 is a study evaluating the investigational 
drug evolocumab. Evolocumab is a monoclonal antibody 
in the new PCSK9 inhibitor class. The purpose of the 
LAPLACE-2 study was to look at the efficacy and safety 
of adding evolocumab to moderate- or high-intensity statin 
therapy and to compare it with ezetimibe. This was a large, 
phase 3 trial with more than 1800 participants who were 
randomly assigned to receive atorvastatin 80 mg or 
rosuvastatin 40 mg for high-intensity statin therapy or to 
atorvastatin 10 mg, rosuvastatin 5 mg, or simvastatin 40 
mg for moderate-intensity statin therapy. The primary 
finding was that the dose of statin did not matter. There 
was an additional 65% reduction in low-density 
lipoprotein cholesterol (LDL-C) when evolocumab was 
added to moderate- or high-intensity statin therapy, and 
that was in comparison with a 20%-25% reduction in LDL-
C when ezetimibe was added to moderate- or high-
intensity statin therapy. The other thing that was very 
interesting about the LAPLACE-2 study is that it reported, 
for the first time, achieved LDL-C levels. Those who 
received a moderate-intensity statin started out with a little 
bit lower LDL-C level than the high-intensity group, but at 
the end of the day, both groups achieved a fairly similar 
LDL-C level: 35-40 mg/dL in the high-intensity group 
compared with 35-45 mg/dL in the moderate-intensity 
group. We are achieving, for the first time, very low LDL-
C levels. It is exciting to contemplate the added efficacy in 
terms of reducing heart attack and stroke from achieving 
very dramatic additional LDL reductions. LAPLACE-2 
was only a 12-week study and it did not address that 
question, but it is basically the model for the design of the 
ongoing FOURIER trial which is testing whether 
evolocumab will further reduce heart attack and stroke 
events in optimally statin-treated patients. That trial will be 
completed circa 2018. In the meantime, we all hope that 
these PCSK9 inhibitors will be available to treat our 
patients who need additional LDL lowering -- such as 
people with genetic hypercholesterolemia whose LDL-C 
levels are still very high on a high-intensity statin, or 
people who are statin-intolerant and are either not able to 
tolerate a statin at all or can only tolerate a suboptimal 
statin dose. It would be very nice to have something to add 
to further lower their LDL-C levels in the meantime (ACC 
2014 Scientific Sessions; Washington, DC; March 29-31, 
2014. Session 402-10).  
 
Radiofrequency Ablation vs Antiarrhythmic Drugs  
 The Radiofrequency Ablation vs Antiarrhythmic Drugs 
as First-Line Therapy of Atrial Fibrillation (RAAFT 2) 
trial showed that radiofrequency catheter ablation with 
pulmonary vein isolation could be successfully performed 
as first-line therapy in patients with atrial fibrillation (AF). 
Most important, when the results are analyzed with other 
data, the study reinforces the conclusion that AF ablation 
for most patients is not a curative procedure. This trial and 
others make it clear that symptomatic and asymptomatic 
recurrences of AF are not uncommon following AF 
ablation and that the efficacy of this procedure, even in 
optimal candidates, is modest: 54.5% of patients with 
persistent or paroxysmal AF treated with first-line ablation 
therapy experienced a documented atrial tachyarrhythmia 
lasting more than 30 sec over the 24-month follow-up 
period. In comparison, 72.1% of patients treated with 
antiarrhythmic medication experienced an atrial 
tachyarrhythmia. This translated into a 44% lower risk of 
symptomatic or asymptomatic AF, atrial flutter, or atrial 
tachycardia over the 2-year period. Recurrent arrhythmias 
were documented by electrocardiogram, Holter, 
transtelephonic monitor, or rhythm strip. Regarding 
secondary end points in the 127-patient trial conducted at 
16 centers in Europe and North America, 59% of patients 
treated with antiarrhythmic medication had a recurrence of 
symptomatic AF, atrial flutter, or atrial tachycardia at 2 
years compared with 47% of patients treated with first-line 
catheter ablation therapy. There were no deaths or stroke 
in the ablation arm, but 4 cases of cardiac tamponade were 
documented. Quality of life was improved with both 
treatments. The RAAFT-2 trial results show that ablation 
is not without its risks. The overall complication rate in the 
trial was 9%, and the rate of cardiac tamponade was 6%. 
These rates are higher than those reported in a recent 
worldwide survey of AF-ablation procedures. RAAFT-2 
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reinforces the recommendations of the 2012 HRS/EHRA 
consensus statement and the 2012 ESC updated AF 
guidelines. Catheter ablation is class 1 recommendation (A 
level of evidence) in patients with paroxysmal AF who 
have failed at least one antiarrhythmic drug. It is only a 
class 2 recommendation (B level of evidence) for 
paroxysmal AF patients who have not yet failed drug 
therapy. In clinical practice, it is uncommon to find a 
patient who is eager to undergo catheter ablation without 
at least one trial of an antiarrhythmic medication. This is 
especially true after a thorough discussion of the risks of 
the procedure, the fact that 30%-50% of patients require a 
repeat procedure, and consideration that the techniques and 
tools used for catheter ablation continue to improve. The 
one subgroup of patients that might benefit from 
immediate ablation of AF comprises those with 
paroxysmal AF and significant sinus-node dysfunction. 
The data suggest the procedure can help control AF and 
eliminate the need for a pacemaker in this patient subgroup 
(Morillo et al, JAMA 2014; 311:692-699 & JAMA 
2014;311: 679-680).  
 
Heparin versus Bivalirudin in STEMI 
 One trial at the American College of Cardiology 2014 
Scientific Sessions took heat like no other: the How 
Effective Are Antithrombotic Therapies in Primary PCI 
(HEAT-PPCI) trial. The single-center randomized trial of 
unfractionated heparin vs bivalirudin (Angiomax, the 
Medicines Company) (with bailout GPIIb/IIIa inhibitors) 
in ST elevation myocardial infarction (STEMI) patients 
surprised by showing a significantly lower rate of major 
adverse cardiac events (MACE) in the heparin-treated 
patients at 28 days and no differences in bleeding 
complications. The trial recruited 1829 patients over a 22-
month period at a single UK hospital with 14 
interventional cardiologists participating in the study. In 
the heparin group, patients received a bolus dose of 70 
units/kg preprocedure, while bivalirudin was given as a 
bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg 
per hour for the duration of the procedure. At four weeks, 
the primary efficacy end point (MACE, defined as all-
cause mortality, cerebrovascular accident, reinfarction, or 
unplanned target lesion revascularization [TLR]) had 
occurred in 8.7% of bivalirudin-treated patients and in 
5.7% of heparin-treated patients, an absolute increased risk 
of 3%. Definite or probable stent thrombosis was 3.4% in 
the bivalirudin group and 0.9% in the heparin group. Minor 
bleeds, as well as major/minor bleeds, were no different 
between groups. Bailout glycoprotein-GP IIb/IIIa-
inhibitor use was similar in both groups, at 13.5% in the 
bivalirudin group and 15.5% in the heparin-treated 
patients. In the HORIZONS trial, bivalirudin alone was 
compared with heparin plus routine GPIIb/IIIa-inhibitor 
use. EuroMAX, the only large randomized trial that 
studied bivalirudin vs heparin (low-molecular-weight or 
unfractionated) with bailout GPIIb/IIIa-inhibitor use in 
both arms, also showed an increase in stent thrombosis in 
the bivalirudin group, although bleeding risk was lower. In 
REPLACE 2, bleeding was lower with bivalirudin, but the 
comparator arm was heparin plus GPIIb/IIIa inhibitors. In 
ACUITY, bleeding rates were lower for the bivalirudin-
monotherapy group but were equivalent in the other two 
trial arms where routine GPIIb/IIIa inhibitors were used on 
top of either heparin/enoxaparin or bivalirudin (Shahzad 
A. Presented at the American College of Cardiology/i2 
Annual Scientific Session. March 31, 2014. Washington, 
DC). 
 
Transcatheter Aortic-Valve Replacement with a Self-
Expanding Prosthesis vs Surgical Aortic Valve 
Replacement 
 A total of 795 patients with severe aortic stenosis and 
an increased risk of death during surgery, underwent 
randomization at 45 centers in the United States. In the as-
treated analysis, the rate of death from any cause at 1 year 
was significantly lower in the TAVR (self-expanding 
transcatheter aortic-valve bioprosthesis) than in the 
surgical group (14.2% vs. 19.1%). In the TAVR group 
there were more vascular complications, the same strokes 
and fewer bleedings and renal dysfunctions compared with 
the surgical group. In a hierarchical testing procedure, 
TAVR was noninferior with respect to echocardiographic 
indexes of valve stenosis, functional status, and quality of 
life. Exploratory analyses suggested a reduction in the rate 
of major adverse cardiovascular and cerebrovascular 
events and no increase in the risk of stroke. In the TAVR 
group more than 20% of the patients required implantation 
of a permanent pacemaker vs 10% of the surgical group. 
In addition, more patients had paravalvular leak at 1 year 
(6.1% vs 0.5%). CoreValve has already indication in the 
USA in patients who are not candidates for operation and 
will ask to have indication for patients with severe aortic 
stenosis and an increased risk of death during surgery 
(Adams et al, N Engl J Med 2014; doi: 
10.1056/NEJMoa1400590. Epub 2014 Mar 29.).  
 
Renal Denervation 
 SYMPLICITY HTN-3 trial was the first randomized 
control trial of renal denervation, where patients with 
therapy-resistant hypertension were randomized in a 2-to-
1 fashion to renal denervation (active treatment) or to a 
sham procedure. Patients were blinded to whether they 
received renal denervation or only renal arteriography. 
Office systolic blood pressure tended to be lower in the 
renal denervation group, but this was far away from 
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reaching statistical significance, and the 24-hour blood 
pressure lowering was not significant between both 
groups. There was no significant difference between both 
groups 6 months after treatment. (Bhatt et al, N Engl J 
Med 2014; doi: 10.1056/NEJMoa1402670. Epub 2014 
Mar 29). 
 
Beta-Blockers vs ACE Inhibitors in Dialysis 
Patients 
 Dr Agarwal recently published in the Nephrology, 
Dialysis, and Transplant journal that beta-blockers are 
better than angiotensin converting enzyme (ACE) 
inhibitors in patients on dialysis. This study looked at 
people with left ventricular hypertrophy and compared 
lisinopril vs atenolol, with cardiovascular mortality, 
myocardial infarction, and stroke as endpoints. Atenolol 
was really working well in these individuals. The primary 
endpoint was regression of left ventricular hypertrophy or 
change in left ventricular mass index from baseline to 12 
months.  The trial was terminated early due to a strong 
signal favoring atenolol in terms of cardiovascular event 
rate and all-cause hospitalizations. Many patients in the 
lisinopril group were hospitalized, and they were 
hospitalized more frequently. The same was true for 
cardiovascular event rates. More patients in the lisinopril 
group had myocardial infarctions, strokes, heart failure 
hospitalizations, and cardiovascular-related death. 
Everything looked better for atenolol. There is a whole 
literature promulgated by the cardiologists about the fact 
that beta-blockers really do not do a good job on left 
ventricular mass regression, whereas ACE inhibitors, 
angiotensin receptor blockers, and even calcium channel 
blockers (CCBs) are better; but in the COSMOS trial, 
where the investigators actually randomly assigned people 
to ACE inhibition or beta blockade using carvedilol, the 
key factor was blood pressure control. It did not matter 
what drug you used; if the blood pressure was controlled, 
you actually saw left ventricular mass regression. Many 
people do not appreciate that beta-blockers reduce blood 
pressure by renin inhibition, not by their effects on the 
sympathetic system. They do affect the sympathetic 
system, but that is not the mechanism through which they 
reduce blood pressure. The advantage in dialysis patients 
is that the renin angiotensin system is almost nonexistent 
in most of those patients because the kidneys are pretty 
much not functioning. The sympathetic nervous system is 
playing a role, however. The ACE inhibitors are essentially 
worthless for blood pressure control in dialysis patients 
because their target is not really functional, whereas the 
beta-blockers are better at lowering blood pressure. Not 
only that, but many of these people on dialysis are prone 
to atrial fibrillation and other arrhythmias, and the beta-
blockers have a role in controlling atrial fibrillation 
(Agarwal et al, Nephrol Dial Transplant 2014;29:672-
681). 
 
Cryoballoon Ablation vs Radiofrequency Ablation of 
Atrial Fibrillation 
 Junxia Xu et al sought to undertake a meta-analysis 
with special emphasis on comparing the efficacy and 
safety between cryoballoon and radiofrequency ablations 
by synthesizing published clinical trials. Articles were 
identified by searching the MEDLINE and EMBASE 
databases before September 2013, by reviewing the 
bibliographies of eligible reports, and by consulting with 
experts in this field. Pulmonary vein isolation (PVI) via 
catheter ablation has become the recommended choice of 
treatment for patients with drug-refractory paroxysmal or 
persistent atrial fibrillation (AF). Conventionally 
radiofrequency current is the preferred source of energy for 
ablation procedures, whereas its application has been 
limited by disrupting tissues due to excess heating or 
generation of inhomogeneous lesions. An alternative 
energy source, cryothermal energy, has recently been 
developed to overcome this limitation. The most 
noteworthy of this study was that there was greater 
improvement in fluoroscopic time and total procedure 
duration in patients referred for cryoballoon ablation than 
those for radiofrequency ablation in PVI of AF. Moreover, 
success rate of PVI, the percentages of recurrence of AF 
and major complications were comparable between the 
two procedures. To our knowledge, this is so far the first 
comprehensive meta-analysis comparing cryoballoon 
ablation with radiofrequency ablation in terms of the 
efficacy and safety for electrical isolation of pulmonary 
veins. There were respectively 469 and 635 patients 
referred for cryoballoon and radiofrequency ablation 
procedures in PVI for the treatment of AF. Distributions of 
age, AF duration, left ventricular ejection fraction, 
previous percutaneous ablation, coronary artery disease, 
hypertension and diabetes were comparable between 
patients referred for cryoballoon and radiofrequency 
ablations (P>0.05). There were more males for 
radiofrequency ablation (79.2%) than cryoballoon ablation 
(72.0%) (P = 0.0284). Left atrium diameter was slightly 
elevated for radiofrequency ablation (42.96% vs 41.89% 
for cryoballoon ablation, P = 0.0212). By contrast, there 
were more patients with paroxysmal AF referred for 
cryoballoon ablation (87.36%) than radiofrequency 
ablation (71.91%) (P = 0.0076). Pooling the results of all 
qualified trials observed that cryoballoon ablation 
significantly reduced fluoroscopic time and total 
procedure time by a weighted mean of 14.13 (P = 0.014) 
minutes and 29.65 (P = 0.006) minutes compared with 
35 
 
radiofrequency ablation, respectively (Xu et al, PLoS One 
2014;9:e90323).  
 
Increased Risk for Cardiovascular Disease Early and 
Late After a Diagnosis of Giant-Cell Arteritis 
According to a Cohort Study 
 Involvement of large arteries is well-documented in 
giant-cell (or temporal) arteritis (GCA). An observational 
cohort study evaluated the risks for incident myocardial 
infarction (MI), cerebrovascular accident (CVA), and 
peripheral vascular disease (PVD) in 3408 patients with 
GCA in comparison with 17,027 age- and gender-matched 
control individuals without baseline cardiovascular disease 
(MI, CVA, or PVD). Data were taken from electronic 
medical records. Among the 3408 patients with GCA (73% 
female; mean age, 73 years), the incidence rates of MI, 
CVA, and PVD were 10.0, 8.0, and 4.2 events per 1000 
person-years, respectively, vs 4.9, 6.3, and 2.0 events per 
1000 person-years, respectively, among controls. The 
hazard ratios-HRs were 1.70 for the combined outcome, 
2.06 for MI, 1.28 for CVA, and 2.13 for PVD. The HRs 
were higher in the first month after GCA diagnosis 
(combined HR, 4.92; HR for MI, 11.89; HR for CVA, 
3.93; HR for PVD, 3.86). A major limitation was the 
missing information on temporal artery biopsies The 
authors concluded that giant-cell arteritis is associated with 
increased risks for MI, CVA, and PVD (Tomasson G, et al, 
Ann Intern Med 2014;160:73-80).  
 
ADJUST-PE Study: Age-Adjusted D-Dimer Cutoff 
Levels Better Rules Out Pulmonary Embolism (PE) 
 Among 3346 patients presenting to the emergency 
department with clinically suspected PE, the prevalence of 
PE was 19%. Patients with a D-dimer value between the 
conventional cutoff of 500 µg/L and their age-adjusted 
cutoff, defined as age × 10 in patients >50 years, did not 
undergo computed tomography pulmonary angiography 
and were left untreated. Among the 2898 patients with 
nonhigh or unlikely probability, 817 patients (28.2%) had 
a D-dimer level <500 µg/L and 337 patients (11.6%) had a 
D-dimer between 500 µg/L and their age-adjusted cutoff. 
The 3-month failure rate in patients with a D-dimer level 
>500 µg/L but below the age-adjusted cutoff was 1 of 331 
patients (0.3%). Among the 766 patients >75 years, of 
whom 673 had a nonhigh clinical probability, using the 
age-adjusted instead of the 500 µg/L cutoff increased the 
proportion of patients in whom PE could be excluded on 
the basis of D-dimer from 43 of 673 patients (6.4%) to 200 
of 673 patients (29.7%), without any additional false-
negative findings. The authors concluded that compared 
with a fixed D-dimer cutoff of 500 µg/L, the combination 
of pretest clinical probability assessment with age-adjusted 
D-dimer cutoff was associated with a larger number of 
patients in whom PE could be considered excluded with a 
low likelihood of subsequent clinical thromboembolism 
(Righini M, et al, JAMA 2014;311:1117-1124).  
 
Catheter Ablation is Superior to Drugs for Maintaining 
Sinus Rhythm in Patients with Persistent AF  
 Patients (n=146; aged 55+9 years) with persistent AF 
were randomly assigned to catheter ablation (CA) or 
antiarrhythmic drugs (AD). After a 3-month blanking 
period, 69 of 98 patients (70.4%) in the CA group and 21 
of 48 patients (43.7%) in the AD group were free of 
arrhythmia (>24h) recurrence (P=0.002); an absolute risk 
difference of 26.6% in favour of CA. The proportion of 
patients free of any recurrence (>30 s) was higher in the 
CA than in the AD group (60.2 vs. 29.2%; P < 0.001) and 
cardioversion was less frequent (34.7 vs 50%; P = 0.018). 
The authors concluded that catheter ablation is superior to 
medical therapy for the maintenance of sinus rhythm in 
patients with persistent AF at 12-month follow-up (Mont 
L, et al, Eur Heart J 2014;35:501-507).  
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253), Thrombophilia (Cohoon KP & Heit JA, Circulation 
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stratification for sudden cardiac death (Goldberger JJ et al, 
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Lomitapide & Mipomersen (Rader DJ & Kastelein JJP 
(Circulation 2014;129:1022-1032), Endovascular therapy 
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